Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nascent polypeptide-associated complex subunit alpha-2 (NACA2) is a protein-coding gene product that functions as part of the nascent polypeptide-associated complex. It binds to emerging nascent polypeptide chains on the ribosome, preventing inappropriate interaction with the signal recognition particle (SRP) and subsequent targeting to the endoplasmic reticulum (ER). This action helps ensure that only secretory peptides are directed to the ER and blocks non-secretory chains from mislocalization. NACA2 is primarily located in the cytoplasm and nucleus and is predicted to be involved in unfolded protein binding and protein targeting to membrane. It has also been identified as a skin-associated autoantigen that can induce monocyte activation and Th1 immune responses in connection with allergic and autoimmune phenomena[1][2][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nascent polypeptide-associated complex subunit alpha-2 (NACA2).